AX-2025-019789 · GHRP-2 · HJ lot HJ-2412-G3929

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.41	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.59	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — C-terminal free acid (+1 Da)	0.21	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	817.4275	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	817.4312	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+4.5	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	5.31	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.72	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.47	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	6.08	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	9.13	min	9.06 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.20	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	67,191	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-2-Nal]-epimer	0.97	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 67,191, and skew follows the reported asymmetry factor of 1.20. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.21 % impurity against a 99.41 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	GHRP-2 — main peak	9.13	4,831,634	99.41	—
2	C-terminal free acid (+1 Da)	9.29	10,207	0.21	+0.984
3	[D-2-Nal]-epimer	8.99	9,721	0.20	0.000
4	des-Lys (−128 Da)	8.89	4,860	0.10	-128.095
5	oxidised Trp (+16 Da)	8.77	3,888	0.08	+15.995
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 817.4275 Da, computed from C45H55N9O6. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 817.4312 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	409.7210	409.7229	0.0019	53.4
1+	818.4348	818.4385	0.0037	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.79	99.41	divergence +0.55 pp vs batch median
Total impurities (% area)	0.21	0.59
Largest single impurity (% area)	not stated	0.21
Water (%)	3.7	5.31
Counter-ion (%)	not stated	4.72
Peptide content (%w/w)	not stated	not determined
Endotoxin (EU/mg)	0.18	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 4 d) → assay. Submitter did not handle the vial.
Assay date: 18 Mar 2025
Submitted to the index: 09 Apr 2025
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: IDENTITY CONSISTENT

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot HJ-2412-G3929 n=14

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-019788	HJ-2412-G3929	Janoshik	2025-Q1	98.98	5.23	104.6	Buyer-sourced	1	FAIL
AX-2025-019790	HJ-2412-G3929	Kestrel	2025-Q1	99.84	5.38	—	Supplier-supplied	1	MARGINAL
AX-2025-019791	HJ-2412-G3929	Medutest	2025-Q1	99.70	5.06	—	Supplier-supplied	1	MARGINAL
AX-2025-019792	HJ-2412-G3929	Nordanalyt	2025-Q1	98.91	5.84	96.7	Buyer-sourced	1	FAIL
AX-2025-019793	HJ-2412-G3929	Nordanalyt	2025-Q1	99.61	5.33	105.9	Supplier-supplied	1	MARGINAL
AX-2025-019794	HJ-2412-G3929	VendorInvestigate	2025-Q1	98.53	5.18	89.5	Buyer-sourced	2	FAIL
AX-2025-019795	HJ-2412-G3929	Janoshik	2025-Q1	99.25	5.92	98.8	Supplier-supplied	2	FAIL
AX-2025-019796	HJ-2412-G3929	Janoshik	2025-Q1	99.59	5.10	96.2	Supplier-supplied	1	MARGINAL
AX-2025-019797	HJ-2412-G3929	Janoshik	2025-Q1	98.97	5.38	103.7	Supplier-supplied	1	FAIL
AX-2025-019798	HJ-2412-G3929	Medutest	2025-Q1	99.62	5.89	103.8	Supplier-supplied	1	MARGINAL
AX-2025-019799	HJ-2412-G3929	VendorInvestigate	2025-Q1	99.04	5.24	97.8	Buyer-sourced	1	MARGINAL
AX-2025-019800	HJ-2412-G3929	VendorInvestigate	2025-Q1	98.30	4.83	—	Buyer-sourced	1	FAIL
AX-2025-019801	HJ-2412-G3929	Janoshik	2025-Q1	99.23	5.17	—	Buyer-sourced	1	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent GHRP-2 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042161	Homopeptide	HOMO-2602-E9033	Medutest	2026-Q2	99.93	3.99	105.6	Supplier-supplied	1	MARGINAL
AX-2026-042302	HJ	HJ-2602-W3148	PeptideMeter	2026-Q2	99.55	1.32	104.9	Supplier-supplied	1	MARGINAL
AX-2026-042159	Homopeptide	HOMO-2602-E9033	Janoshik	2026-Q2	99.39	3.77	—	Laboratory-retained	1	MARGINAL
AX-2026-042303	HJ	HJ-2602-W3148	PeptideMeter	2026-Q2	99.12	1.24	98.0	Supplier-supplied	1	MARGINAL
AX-2026-042160	Homopeptide	HOMO-2602-E9033	Medutest	2026-Q2	99.62	4.50	99.5	Supplier-supplied	1	MARGINAL
AX-2026-043489	WXT	WXT-2605-U5824	PeptideMeter	2026-Q2	98.83	5.76	96.6	Supplier-supplied	2	FAIL
AX-2026-042157	Homopeptide	HOMO-2602-E9033	PeptideMeter	2026-Q2	99.93	4.32	—	Supplier-supplied	1	MARGINAL
AX-2026-042158	Homopeptide	HOMO-2602-E9033	Janoshik	2026-Q2	99.59	4.35	89.8	Buyer-sourced	2	MARGINAL

Other recent HJ records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042368	Semax	HJ-2603-V4363	Nordanalyt	2026-Q3	99.17	7.26	106.3	Supplier-supplied	1	MARGINAL
AX-2026-042347	Semaglutide	HJ-2608-C3931	VendorInvestigate	2026-Q3	98.80	3.41	100.2	Buyer-sourced	1	MARGINAL
AX-2026-042367	Semax	HJ-2603-V4363	Kestrel	2026-Q3	99.10	6.78	93.9	Supplier-supplied	1	MARGINAL
AX-2026-042348	Semaglutide	HJ-2608-C3931	Nordanalyt	2026-Q3	99.52	4.19	—	Supplier-supplied	1	MARGINAL
AX-2026-042290	GHRP-6	HJ-2603-R2258	Janoshik	2026-Q3	99.71	3.05	—	Supplier-supplied	2	MARGINAL
AX-2026-042287	GHRP-6	HJ-2603-R2258	VendorInvestigate	2026-Q3	98.79	2.43	90.9	Buyer-sourced	2	FAIL
AX-2026-042288	GHRP-6	HJ-2603-R2258	Kestrel	2026-Q3	99.93	2.82	92.8	Supplier-supplied	2	MARGINAL
AX-2026-042346	Semaglutide	HJ-2608-C3931	VendorInvestigate	2026-Q3	99.40	3.48	—	Buyer-sourced	1	MARGINAL